"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...

In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...

With cases of avian influenza A(H5N1) continuing to rise among cattle and humans in the US, scientists and government health officials are preparing for the potential of the virus adapting to enable ...

Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...

A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes ... efficacy at 100X lower doses than conventional mRNA. "This advancement solves a longstanding challenge ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The randomized placebo-controlled ...